*June 2019* by Nichole Tucker for Targeted Oncology
Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have made a well-documented impact on outcomes for patients with non–small cell lung cancer (NSCLC) who harbor EGFR mutations; the challenge is once a patient develops resistance to an EGFR TKI. Two abstracts presented at the 2019 ASCO Annual Meeting analyzed potential combinations with osimertinib (Tagrisso), a third-generation EGFR TKI, with additional agents to potentially overcome resistance mutations following progression in patients with EGFR-mutant NSCLC. Read the entire article.
